Royal Fund Management’s Tvardi Therapeutics TVRD Stock Holding History

Royal Fund Management’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1	Closed	–	–	717
2019 Q3	$0	Buy	+1	New	+$831	﹤0.01%	683

Other funds holding TVRD

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Royal Fund Management's TVRD Position: Q4 2019 in Review

Royal Fund Management sold out of Tvardi Therapeutics (TVRD) in Q4 2019, closing a stake of 1 share.

Royal Fund Management first reported a position in TVRD in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 151 funds tracked by Wall St. Rank hold TVRD as of Q4 2019.

Royal Fund Management reported no remaining Tvardi Therapeutics position as of Q4 2019 after selling out during the quarter.
Royal Fund Management sold 1 Tvardi Therapeutics share in Q4 2019.
Royal Fund Management first reported a position in Tvardi Therapeutics in Q3 2019 and held it in 1 quarter.
Royal Fund Management's Tvardi Therapeutics position peaked at $0 in Q3 2019.
151 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2019.

Based on Royal Fund Management's 13F filing for Q4 2019, filed 11 May 2020.